{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T04:29:11Z","timestamp":1782361751385,"version":"3.54.5"},"reference-count":37,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":5637,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1093\/annonc\/mdh319","type":"journal-article","created":{"date-parts":[[2004,7,26]],"date-time":"2004-07-26T18:40:48Z","timestamp":1090867248000},"page":"1194-1203","source":"Crossref","is-referenced-by-count":257,"title":["Single nucleotide polymorphisms and outcome in docetaxel\u2013cisplatin-treated advanced non-small-cell lung cancer"],"prefix":"10.1016","volume":"15","author":[{"given":"D.","family":"Isla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sarries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Rosell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Domine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Taron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Lopez-Vivanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Camps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Botia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Nu\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sanchez-Ronco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lopez-Brea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Barneto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Paredes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Artal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lianes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdh319_bb0010","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2003.12.046","article-title":"Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group","volume":"21","author":"Fossella","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh319_bb0015","first-page":"4899","article-title":"Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells","volume":"62","author":"Furuta","year":"2002","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdh319_bb0020","first-page":"5299","article-title":"Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer","volume":"9","author":"Reed","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdh319_bb0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0304-3835(01)00690-5","article-title":"Loss of heterozygosity of nucleotide excision repair factors in sporadic ovarian, colon and lung carcinomas: implication for their roles of carcinogenesis in human solid tumors","volume":"174","author":"Takebayashi","year":"2001","journal-title":"Cancer Lett"},{"key":"10.1093\/annonc\/mdh319_bb0030","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/carcin\/21.8.1527","article-title":"Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis","volume":"21","author":"Cheng","year":"2000","journal-title":"Carcinogenesis"},{"key":"10.1093\/annonc\/mdh319_bb0035","first-page":"801","article-title":"Expression in normal human tisssues of five nucleotide excision repair genes measured simultaneously by multiplex reverse transcription-polymerase chain reaction","volume":"8","author":"Cheng","year":"1999","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1093\/annonc\/mdh319_bb0040","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0921-8777(00)00051-3","article-title":"DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes","volume":"461","author":"Vogel","year":"2000","journal-title":"Mutat Res"},{"key":"10.1093\/annonc\/mdh319_bb0045","first-page":"4103","article-title":"Reduced DNA repair capacity in lung cancer patients","volume":"56","author":"Wei","year":"1996","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdh319_bb0050","first-page":"4760","article-title":"Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy","volume":"55","author":"Zeng-Rong","year":"1995","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdh319_bb0055","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/jnci\/94.14.1091","article-title":"An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer","volume":"94","author":"Bosken","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdh319_bb0060","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1172\/JCI117388","article-title":"Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy","volume":"94","author":"Dabholkar","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdh319_bb0065","first-page":"645","article-title":"Association between the level of ERCC1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells","volume":"20","author":"Li","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdh319_bb0070","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1200\/JCO.1998.16.1.309","article-title":"ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy","volume":"16","author":"Metzger","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh319_bb0075","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1200\/JCO.2001.19.23.4298","article-title":"ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil","volume":"19","author":"Shirota","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh319_bb0080","first-page":"2286","article-title":"Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small-cell lung cancer","volume":"8","author":"Lord","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdh319_bb0085","first-page":"604","article-title":"Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans","volume":"58","author":"Shen","year":"1998","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdh319_bb0090","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/sj.tpj.6500109","article-title":"Efficient discovery of single-nuceotide polymorphisms in coding regions of human genes","volume":"2","author":"Hu","year":"2002","journal-title":"Pharmacogenomics J"},{"key":"10.1093\/annonc\/mdh319_bb0095","first-page":"13","article-title":"A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues","volume":"382","author":"Yu","year":"1997","journal-title":"Mutat Res"},{"key":"10.1093\/annonc\/mdh319_bb0100","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1093\/carcin\/21.11.1977","article-title":"Identification of single nucleotide polymorphisms in human DNA repair genes","volume":"21","author":"Ford","year":"2000","journal-title":"Carcinogenesis"},{"key":"10.1093\/annonc\/mdh319_bb0105","first-page":"1354","article-title":"Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients","volume":"61","author":"Spitz","year":"2001","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdh319_bb0110","first-page":"7430","article-title":"Functional significance of XPD polymorphic variants: attenuated apoptosis in human lymphoblastoid cells with the XPD 312 Asp\/Asp genotype","volume":"61","author":"Seker","year":"2001","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdh319_bb0115","first-page":"8654","article-title":"A xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer","volume":"61","author":"Park","year":"2001","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdh319_bb0120","first-page":"980","article-title":"Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p3R2 as well as hRRM2 subunits","volume":"63","author":"Xue","year":"2003","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdh319_bb0125","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s003359901114","article-title":"Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1)","volume":"10","author":"Pitterle","year":"1999","journal-title":"Mamm Genome"},{"issue":"Suppl 7","key":"10.1093\/annonc\/mdh319_bb0130","first-page":"S82","article-title":"Tumor genotype RRM1 expression and outcome of patients with lung cancer","volume":"38","author":"Bepler","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdh319_bb0135","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00008571-200106000-00003","article-title":"The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells","volume":"11","author":"Hitzl","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1093\/annonc\/mdh319_bb0140","first-page":"4955","article-title":"MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients","volume":"62","author":"Illmer","year":"2002","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdh319_bb0145","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1056\/NEJMoa021986","article-title":"Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1","volume":"348","author":"Siddiqui","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdh319_bb0150","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumor","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdh319_bb0155","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2165\/00129785-200303020-00001","article-title":"Implications of genetic testing in the management of colorectal cancer","volume":"3","author":"Stoehlmacher","year":"2003","journal-title":"Am J Pharmacogenomics"},{"key":"10.1093\/annonc\/mdh319_bb0160","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(02)08065-0","article-title":"Polymorphism of the thymidilate synthase gene and outcome of acute lymphoblastic leukaemia","volume":"359","author":"Krajinovic","year":"2002","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdh319_bb0165","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.1038\/sj.onc.1206847","article-title":"Regulation of telomerase reverse transcriptase gene activity by upstream stimulatory factor","volume":"22","author":"Goueli","year":"2003","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdh319_bb0170","first-page":"2898","article-title":"A novel single nucleotide polymorphism within the 5\u2032 tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional actvity","volume":"63","author":"Mandola","year":"2003","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdh319_bb0175","first-page":"1261","article-title":"Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2","volume":"55","author":"Dabholkar","year":"1995","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdh319_bb0180","first-page":"123","article-title":"XPD and XRCC1 genetic polymorphisms are associated with overall survival in advanced NCLC patients treated with platinum chemotherapy","volume":"22","author":"Gurubhagavatula","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdh319_bb0185","first-page":"1377","article-title":"Gene-environment interaction for the ERCC2 polymorphisms and cumulative cigarette smoking exposure in lung cancer","volume":"62","author":"Zhou","year":"2002","journal-title":"Cancer Res"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdh319_bb0190","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/S0169-5002(03)92012-5","article-title":"Randomised phase III trial of docetaxel\/carboplatin vs. MIC\/MVP chemotherapy in inoperable advanced non-small cell lung cancer. Do XPD polymorphisms predict for sensitivity or resistance to platinum based chemotherapy","volume":"41","author":"Booton","year":"2003","journal-title":"Lung Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420310553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420310553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/15\/8\/1194\/13134254\/mdh319.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T22:31:36Z","timestamp":1582237896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753420310553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["S0923753420310553"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdh319","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2004,8]]}}}